191 related articles for article (PubMed ID: 8726415)
1. Clinical and immunological studies in advanced cancer patients sequentially treated with anti CD3 monoclonal antibody (OKT3) and interleukin-2.
Borrione P; Montacchini L; Beggiato E; Pileri A; Bianchi A; Massaia M
Leuk Lymphoma; 1996 Apr; 21(3-4):325-30. PubMed ID: 8726415
[TBL] [Abstract][Full Text] [Related]
2. Detection of hyperreactive T cells in multiple myeloma by multivalent cross-linking of the CD3/TCR complex.
Massaia M; Bianchi A; Attisano C; Peola S; Redoglia V; Dianzani U; Pileri A
Blood; 1991 Oct; 78(7):1770-80. PubMed ID: 1832993
[TBL] [Abstract][Full Text] [Related]
3. Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects.
Sosman JA; Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; O'Boyle K; Fisher RI; Boldt DH; Doroshow J
J Clin Oncol; 1993 Aug; 11(8):1496-505. PubMed ID: 8336188
[TBL] [Abstract][Full Text] [Related]
4. A phase IA/IB trial of anti-CD3 murine monoclonal antibody plus low-dose continuous-infusion interleukin-2 in advanced cancer patients.
Sosman JA; Kefer C; Fisher RI; Jacobs CD; Pumfery P; Ellis TM
J Immunother Emphasis Tumor Immunol; 1995 Apr; 17(3):171-80. PubMed ID: 7613643
[TBL] [Abstract][Full Text] [Related]
5. CD30-antigen-specific targeting and activation of T cells via murine bispecific monoclonal antibodies against CD3 and CD28: potential use for the treatment of Hodgkin's lymphoma.
Pohl C; Denfeld R; Renner C; Jung W; Bohlen H; Sahin U; Hombach A; van Lier R; Schwonzen M; Diehl V
Int J Cancer; 1993 Jul; 54(5):820-7. PubMed ID: 7686889
[TBL] [Abstract][Full Text] [Related]
6. Influence of interleukin-2 regimens on circulating populations of lymphocytes after adoptive transfer of anti-CD3-stimulated T cells: results from a phase I trial in cancer patients.
Curti BD; Ochoa AC; Urba WJ; Alvord WG; Kopp WC; Powers G; Hawk C; Creekmore SP; Gause BL; Janik JE; Holmlund JT; Kremers P; Fenton RG; Miller L; Sznol M; Smith JW; Sharfman WH; Longo DL
J Immunother Emphasis Tumor Immunol; 1996 Jul; 19(4):296-308. PubMed ID: 8877723
[TBL] [Abstract][Full Text] [Related]
7. Augmentation of cell number and LAK activity in peripheral blood mononuclear cells activated with anti-CD3 and interleukin-2. Preliminary results in children with acute lymphocytic leukemia and neuroblastoma.
Anderson PM; Bach FH; Ochoa AC
Cancer Immunol Immunother; 1988; 27(1):82-8. PubMed ID: 3260824
[TBL] [Abstract][Full Text] [Related]
8. Activation of human T cells obtained pre- and post-interleukin-2 (IL-2) therapy by anti-CD3 monoclonal antibody plus IL-2: implications for combined in vivo treatment.
Weil-Hillman G; Schell K; Segal DM; Hank JA; Sosman JA; Sondel PM
J Immunother (1991); 1991 Aug; 10(4):267-77. PubMed ID: 1834166
[TBL] [Abstract][Full Text] [Related]
9. [Lymphocyte activation markers in patients with ovarian cancer].
Nowicka A; Rogala E; Bednarek W; Barczyński B; Wertel I; Piekarczyk W; Kotarski J
Ginekol Pol; 2012 Oct; 83(10):737-43. PubMed ID: 23383558
[TBL] [Abstract][Full Text] [Related]
10. CD3-induced T-cell activation in the bone marrow of myeloma patients: major role of CD4+ cells.
Bianchi A; Montacchini L; Barral P; Borrione P; Attisano C; Orsini E; Boccadoro M; Pileri A; Massaia M
Br J Haematol; 1995 Jul; 90(3):625-32. PubMed ID: 7647004
[TBL] [Abstract][Full Text] [Related]
11. Rapid generation of antiplasma cell activity in the bone marrow of myeloma patients by CD3-activated T cells.
Massaia M; Attisano C; Peola S; Montacchini L; Omedé P; Corradini P; Ferrero D; Boccadoro M; Bianchi A; Pileri A
Blood; 1993 Sep; 82(6):1787-97. PubMed ID: 8400233
[TBL] [Abstract][Full Text] [Related]
12. Preclinical studies for adoptive immunotherapy in bone marrow transplantation. Generation of anti-CD3 activated cytotoxic T cells from normal donors and autologous bone marrow transplant candidates.
Ueda M; Joshi ID; Dan M; Uberti JP; Chou TH; Sensenbrenner LL; Lum LG
Transplantation; 1993 Aug; 56(2):351-6. PubMed ID: 8356589
[TBL] [Abstract][Full Text] [Related]
13. Enhancement by interleukin 4 of interleukin 2- or antibody-induced proliferation of lymphocytes from interleukin 2-treated cancer patients.
Treisman J; Higuchi CM; Thompson JA; Gillis S; Lindgren CG; Kern DE; Ridell SR; Greenberg PD; Fefer A
Cancer Res; 1990 Feb; 50(4):1160-4. PubMed ID: 2153452
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2.
Kroesen BJ; Buter J; Sleijfer DT; Janssen RA; van der Graaf WT; The TH; de Leij L; Mulder NH
Br J Cancer; 1994 Oct; 70(4):652-61. PubMed ID: 7917912
[TBL] [Abstract][Full Text] [Related]
15. Clinical and immunological effects of treatment with murine anti-CD3 monoclonal antibody along with interleukin 2 in patients with cancer.
Hank JA; Albertini M; Wesly OH; Schiller JH; Borchert A; Moore K; Bechhofer R; Storer B; Gan J; Gambacorti C
Clin Cancer Res; 1995 May; 1(5):481-91. PubMed ID: 9816007
[TBL] [Abstract][Full Text] [Related]
16. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis.
Cope AP; Londei M; Chu NR; Cohen SB; Elliott MJ; Brennan FM; Maini RN; Feldmann M
J Clin Invest; 1994 Aug; 94(2):749-60. PubMed ID: 8040330
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibodies to the CD5 antigen can provide the necessary second signal for activation of isolated resting T cells by solid-phase-bound OKT3.
Ceuppens JL; Baroja ML
J Immunol; 1986 Sep; 137(6):1816-21. PubMed ID: 3091691
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-2 bolus therapy induces immediate and selective disappearance from peripheral blood of all lymphocyte subpopulations displaying natural killer activity: role of cell adhesion to endothelium.
Salvo G; Samoggia P; Masciulli R; Boccoli G; Allavena P; Mariani G; Bullo A; Montesoro E; Bulgarini D; Carlini P
Eur J Cancer; 1992; 28A(4-5):818-25. PubMed ID: 1524901
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies.
Wong JT; Pinto CE; Gifford JD; Kurnick JT; Kradin RL
J Immunol; 1989 Nov; 143(10):3404-11. PubMed ID: 2509557
[TBL] [Abstract][Full Text] [Related]
20. Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: identification and isolation of effector subsets.
Ochoa AC; Hasz DE; Rezonzew R; Anderson PM; Bach FH
Cancer Res; 1989 Feb; 49(4):963-8. PubMed ID: 2521457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]